使用生成对抗网络用于阿尔茨海默病分类的最小数据的特殊性能
Pui Ching Wong1, Shahrum Shah Abdullah2, Mohd Ibrahim Shapiai3
1Biologically Inspired System and Technology Laboratory, Department of Electronic Systems Engineering, Malaysia-Japan International Institute of Technology, Universiti Teknologi Malaysia, Kuala Lumpur, Malaysia. puiching1997@graduate.utm.my.
Scientific reports
|July 23, 2024
概括
生成对抗性网络 (GAN) 解决了阿尔茨海默病 (AD) 分类中的数据稀缺问题. 这种深度学习方法可以在减少医学成像数据的情况下实现高精度,克服隐私和不平衡的挑战.
科学领域:
- 人工智能的人工智能
- 医疗成像医学成像
- 神经科学是一个神经科学.
背景情况:
- 由于隐私法规,阿尔茨海默病 (AD) 分类的深度学习受到医疗成像数据稀缺的限制.
- 像OASIS这样的开放访问数据集往往呈现出不平衡的类分布,进一步复杂化了模型训练.
研究的目的:
- 提出和评估一个生成对抗网络 (GAN) 综合方法,以提高阿尔茨海默氏症的疾病分类,有限的数据.
- 解决AD研究的医学图像数据集中的数据稀缺性和阶级不平衡问题.
主要方法:
- 利用生成对抗网络 (GAN) 来增强数据,生成合成MRI数据.
- 训练了GAN模型,使用来自Open Access系列成像研究 (OASIS) 数据库的实验数据.
- 将合成数据集成到预训练的卷积神经网络 (CNN) 中,用于多阶段AD分类.
主要成果:
- 通过减少数据集,实现了超过80%的多阶段阿尔茨海默病分类准确度.
- 证明了GAN在克服医疗图像分析数据短缺方面的有效性.
- 显示了与在更大,更平衡的数据集上训练的模型相似的准确性.
结论:
- 生成对抗性网络 (GAN) 为阿尔茨海默病分类数据不足的挑战提供了可行的解决方案.
- 基于GAN的数据增强可以显著提高医学成像研究中的深度学习模型性能.
- 这种方法有望推动AD诊断和研究,尽管数据获取有限.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172


